Revolution Medicines(RVMD)
$159.82-2.87 (-1.76%)
RVMD
Revolution Medicines stock drug pipeline
$159.82
At close:-2.87 (-1.76%)
Want to see RVMD full AI Analyst Report?
Revolution Medicines (RVMD) Drug Pipeline
1,047 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Revolution Medicines, Inc. (RVMD) have in its pipeline
Revolution Medicines RVMD is currently developing the following drugs: Gemcitabine, Nab-Paclitaxel, Daraxonrasib, Zoldonrasib, Pembrolizumab, Zoldonrasib, Pemetrexed + Cisplatin /Carboplatin, Leucovorin, Oxaliplatin, Gemcitabine, 5-Fluorouracil, Irinotecan, Nab-Paclitaxel, Zoldonrasib, Nab-Paclitaxel, Gemcitabine, Daraxonrasib, Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + Pemetrexed, Cetuximab, Daraxonrasib, Rmc-5127, Daraxonrasib, Rmc-6236, Tng462, Rmc-9805, Docetaxel, Daraxonrasib, Gemcitabine, Nab-Paclitaxel, Oxaliplatin, Irinotecan, Rmc-6236, Leucovorin, 5-Fluorouracil, Liposomal Irinotecan, Gemcitabine, Bevacizumab, Nab-Paclitaxel, Rmc-6236, Cetuximab, Rmc-9805, Mfolfox6 Regimen, Mfolfirinox Regimen, Pembrolizumab, Rmc-6291, Pemetrexed, Rmc-6236, Carboplatin, Cisplatin, Rmc-9805, Assigned Interventions, Rmc-6236, Rmc-9805, Rmc-6291, Rmc-6236, Rmc-5552. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

